Researchers have identified a compound that reduces the levels of a key enzyme that regulates activity in pain receptors, pointing the way to new therapies for treating some forms of back pain, shingles, and other types of chronic neuropathic pain.
For older men and women without dementia, the impact of late-life blood pressure on brain pathology varies with their history of midlife hypertension, according to a study published online June 4 in Neurology.
Patients with chronic obstructive pulmonary disease are twice as likely to develop mild cognitive impairment.
The newer non-ergoline-derived dopaminergic agents appear to cause only minimal endocrine effects when used to treat idiopathic Parkinson’s disease.
There is no evidence of an obesity paradox in patients with stroke, suggesting that previous findings were an artifact of selection bias, according to a study published online June 2 in JAMA Neurology.
Even with good office procedures, most practices are plagued by claim denials, a hassle that is expected to increase in the coming years, according to an article published May 8 in Medical Economics.
Modifying the Course of Multiple Sclerosis: The Growing Treatment Armamentarium
Neurologist Andrew D. Goodman, MD, FAAN, explains the benefits of the mechanisms behind the new multiple sclerosis medications.
Factors such as the aging and growth of the population accompanied by improvements in early detection and treatment are expected to contribute to the growth of the number of cancer survivors in the United States, according to research published online June 1 in CA: A Cancer Journal for Clinicians.
Although physicians regularly recommend high-intensity, aggressive, life-prolonging care for their terminally ill patients, the vast majority would choose to forgo such care for themselves at the end of life, according to a study published online May 28 in PLOS ONE.
Taking more than 5 medications was associated with fatigue and memory problems in multiple sclerosis patients, a new study reports.